ストックスクリーナーアプリを入手
5.37
10.20%
-0.61
アフターアワーズ：
5.24
-0.13
-2.42%
前日終値:
$5.98
開ける：
$5.6259
24時間の取引高:
121.50K
Relative Volume:
4.11
時価総額：
$50.13M
収益：
-
当期純損益:
$-37.72M
株価収益率:
-0.7112
EPS:
-7.5501
ネットキャッシュフロー:
$-52.35M
1週間 パフォーマンス:
-4.45%
1か月 パフォーマンス:
+12.11%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$5.36
$6.06
1週間の範囲:
$5.05
$6.10
52週間の値動き範囲:
$4.21
$6.625
Leonabio Inc Stock (LONA) Company Profile
名前
Leonabio Inc
セクター
電話
(425) 620-8501
住所
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
5.37 | 55.83M | 0 | -37.72M | -52.35M | -7.5501 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-19 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-09-19 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-09-04 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-09-04 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | ダウングレード | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | 開始されました | Rodman & Renshaw | Buy |
| 2022-10-17 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | 開始されました | Mizuho | Buy |
| 2022-06-23 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | ダウングレード | Jefferies | Buy → Hold |
| 2022-06-23 | ダウングレード | Stifel | Buy → Hold |
| 2022-05-10 | 開始されました | BTIG Research | Buy |
| 2022-04-21 | 開始されました | Berenberg | Buy |
| 2021-12-15 | 開始されました | Goldman | Neutral |
| 2020-10-13 | 開始されました | Goldman | Buy |
| 2020-10-13 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-13 | 開始されました | Jefferies | Buy |
| 2020-10-13 | 開始されました | Stifel | Buy |
すべてを表示
Leonabio Inc (LONA) 最新ニュース
Athira Pharma (LONA) 10K Form and SEC Filings 2026 $LONA - MarketBeat
Cantor Fitzgerald initiates Leona Bio stock with overweight rating By Investing.com - Investing.com Australia
LeonaBio initiated with an Overweight at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald Initiates Coverage on LeonaBio With Overweight Rating - marketscreener.com
LONA Technical Analysis & Stock Price Forecast - Intellectia AI
LONA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LeonaBio, Inc. (prev. ATHA) (LONA) Stock Price Today | Live Chart & News - Traders Union
LeonaBio Shares Rise After Mizuho Securities Upgrade - marketscreener.com
LeonaBio (LONA) Receives Upgrade to Outperform by Mizuho | LONA Stock News - GuruFocus
Mizuho upgrades LeonaBio stock rating on breast cancer drug potential By Investing.com - Investing.com South Africa
Mizuho upgrades LeonaBio stock rating on breast cancer drug potential - Investing.com
Mizuho Securities Initiates LeonaBio(LONA.US) With Buy Rating, Announces Target Price $10 - 富途牛牛
LeonaBio (ATHA) proxy asks investors to back warrant share issuances and 2026 equity plan - stocktitan.net
LeonaBio appoints Mark Kubik as chief business officer By Investing.com - Investing.com Nigeria
Leonabio, Inc. Announces the Appointment of Mark F. Kubik as Chief Business Officer - marketscreener.com
LeonaBio (LONA) Names Mark Kubik as New Chief Business Officer - GuruFocus
LeonaBio appoints Mark Kubik as chief business officer - Investing.com
LeonaBio, Inc. Appoints Mark F. Kubik as Chief Business Officer to Drive Business Development Strategy - Quiver Quantitative
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer - marketscreener.com
Biopharma deal veteran to drive LeonaBio’s Phase 3 breast cancer drug - Stock Titan
Leonabio Inc files for offering of up to 58.5 million shares of common stock by the selling stockholders - marketscreener.com
Leonabio Inc Files For Offering Of Up To 58.5 Million Shares Of Common Stock By The Selling Stockholders - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA" - Investing News Network
LONA Stock Price and Chart — NASDAQ:LONA - TradingView
Athira Pharma (ATHA) Options to Be Delisted on January 12th - GuruFocus
LONA Stock Price, News & Analysis - Stock Titan
Athira Pharma Rebrands as LeonaBio, Refocusing on Oncology - TipRanks
Athira Pharma announces name change to LeonaBio - TipRanks
Athira Pharma roars into the new year with rebrand to LeonaBio - Fierce Pharma
Athira Pharma changes name, ticker symbol - MSN
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy - Investing.com Nigeria
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy By Investing.com - Investing.com South Africa
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” - Yahoo Finance
New breast cancer drug moves into late testing with $236M funding deal - Stock Titan
Athira Pharma (NASDAQ: ATHA) posts $6.6M Q3 loss; ATH-1105 study shows favorable safety, CNS penetration - Stock Titan
Athira Pharma announces reverse stock split - marketscreener.com
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 - GlobeNewswire
ATHA SEC FilingsAthira Pharma, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
ATHA Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Breakthrough ALS Drug ATH-1105 Achieves Key Safety Milestones, Targets Patient Trials Late 2025 - Stock Titan
Athira Pharma Slides As Insider Purchases Lose Another US$89k - simplywall.st
ATHA Stock Price, News & Analysis - stocktitan.net
Athira Pharma's ALS Drug Shows Promising Neuroprotective Effects in Key Preclinical Study - Stock Titan
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - marketscreener.com
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology - marketscreener.com
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference - Stock Titan
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND - marketscreener.com
Athira Pharma, Inc. Plans to Further Extend the Current OLEX for the Phase 2/3 LIFT-AD and Phase 2 ACT-AD Trials - marketscreener.com
Athira Pharma Provides 2023 Pipeline Outlook - marketscreener.com
Goldman Sachs Adjusts Price Target for Athira Pharma to $3 From $11, Maintains Neutral Rating - marketscreener.com
Leonabio Inc (LONA) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):